ProCE Banner Activity

UNITY-NHL Phase IIb Trial: Efficacy and Safety of Umbralisib Monotherapy in Patients With R/R Marginal Zone Lymphoma

Slideset Download
Conference Coverage
Umbralisib monotherapy demonstrated clinical activity in patients with relapsed/refractory marginal zone lymphoma previously treated with CD20-directed therapy.

Released: June 07, 2019

Expiration: June 05, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro